Juno Pharmaceuticals Corporation

Pharmac, the agency that decides which medicines are funded in New Zealand, today said it was looking to widen access to four products as part of the first public consultation following its receipt of

Glenmark Pharmaceuticals has launched the first biosmilar to Novo Nordisk ’s glucagon‐like peptide 1 (GLP-1) receptor agonist Victoza (liraglutide) in India, kicking off 2024 with a high-profile deb

At the midway point of 2023, dealmaking for big pharma had roared back to life following relative austerity in the previous two years, as credit became harder to come by, interest rates spiked, and le

Glenmark Pharmaceuticals Limited has launched the first biosmilar to Novo Nordisk ’s glucagon‐like peptide 1 (GLP-1) receptor agonist Victoza (liraglutide) in India, kicking off 2024 with a high-pro